InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…
Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Data spans five abstracts including two oral presentations with important findings for…
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its…
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as…
National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations
The Medidata Data Experience offering will enable the National Cancer Institute Lead…
Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025
ASHEVILLE, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health, a healthcare…
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX)…
Invictus Pharmacy First to Accept Crypto for Prescriptions
Disrupting pharmacy payments with ETH, SOL, and XRP acceptance nationwide; online rollout set…
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as…